Deep learning in rheumatological image interpretation
Nature Reviews Rheumatology, Published online: 08 February 2024; doi:10.1038/s41584-023-01074-5Deep learning is a powerful technique with great potential for the analysis and interpretation of rheumatological images. To successfully use deep learning, rheumatologists should understand the tasks involved in image processing and the potential confounders and limitations that can affect the analysis of clinical data. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 8, 2024 Category: Rheumatology Authors: Berend C. Stoel Marius Staring Monique Reijnierse Annette H. M. van der Helm-van Mil Source Type: research
GWAS data help unravel Dupuytren disease
Nature Reviews Rheumatology, Published online: 08 February 2024; doi:10.1038/s41584-024-01091-yA meta-analysis of data from six genome-wide association study cohorts implicates several signalling pathways, including Hedgehog and Notch signalling, in Dupuytren disease. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 8, 2024 Category: Rheumatology Authors: Sarah Onuora Source Type: research
ZEB2 promotes formation of age-related B cells
Nature Reviews Rheumatology, Published online: 08 February 2024; doi:10.1038/s41584-024-01089-6Age-related B cells (ABCs) have pathogenic roles in autoimmune diseases. Research has now identified ZEB2 as the transcription factor that mediates differentiation into ABCs. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 8, 2024 Category: Rheumatology Authors: Robert Phillips Source Type: research
Sodium channel Nav1.7 regulates chondrocyte biology and OA progression
Nature Reviews Rheumatology, Published online: 07 February 2024; doi:10.1038/s41584-024-01090-zThe voltage-gated sodium channel Nav1.7 is expressed on chondrocytes, regulates chondrocyte biology and osteoarthritis progression, and is a promising dual target for modifying disease while providing pain relief in osteoarthritis. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 7, 2024 Category: Rheumatology Authors: Jessica McHugh Source Type: research
Treatment of non-systemic juvenile idiopathic arthritis
Nature Reviews Rheumatology, Published online: 06 February 2024; doi:10.1038/s41584-024-01079-8Juvenile idiopathic arthritis treatment has evolved with new therapies, early remission goals and global efforts, including randomized trials and a treat-to-target strategy. This Review summarizes current evidence and therapeutic approaches to the management of non-systemic phenotypes of juvenile idiopathic arthritis. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 6, 2024 Category: Rheumatology Authors: Susan Shenoi Gerd Horneff Amita Aggarwal Angelo Ravelli Source Type: research
The gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever
Nature Reviews Rheumatology, Published online: 06 February 2024; doi:10.1038/s41584-023-01071-8This Review discusses the interplay of the gut microbiome and the immune system in the context of systemic lupus erythematosus. Dysbiosis and gut-barrier dysfunction are implicated in promoting disease and are potential therapeutic targets. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 6, 2024 Category: Rheumatology Authors: Gregg J. Silverman Doua F. Azzouz Nicolas Gisch Abhimanyu Amarnani Source Type: research
Factors identified that predict resolution of subclinical synovitis
Nature Reviews Rheumatology, Published online: 05 February 2024; doi:10.1038/s41584-024-01087-8New findings provide insight into the natural history of subclinical synovitis, a reported predictor of the development of rheumatoid arthritis, and identify various factors associated with its reversal. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 5, 2024 Category: Rheumatology Authors: Jessica McHugh Source Type: research
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Nature Reviews Rheumatology, Published online: 01 February 2024; doi:10.1038/s41584-024-01085-wPublisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - February 1, 2024 Category: Rheumatology Authors: Zolt án Szekanecz Maya H. Buch Christina Charles-Schoeman James Galloway George A. Karpouzas Lars Erik Kristensen Steven R. Ytterberg Attila Hamar Roy Fleischmann Source Type: research
Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow
Nature Reviews Rheumatology, Published online: 26 January 2024; doi:10.1038/s41584-024-01083-yAs in rheumatoid arthritis, achieving low disease activity or remission in psoriatic arthritis (PsA) remains a challenge and unmet need for many individuals. However, the complex pathogenesis, heterogeneity and varied tissue involvement in PsA mean that dedicated definitions and novel solutions are required for difficult-to-treat disease. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 26, 2024 Category: Rheumatology Authors: Stefan Siebert Helena Marzo-Ortega Source Type: research
Is cell therapy no better than steroid injection?
Nature Reviews Rheumatology, Published online: 25 January 2024; doi:10.1038/s41584-024-01082-zNew findings suggest that current cell therapy approaches are not superior to a simple corticosteroid injection for the treatment of osteoarthritis, calling into question the role of existing cell therapies and highlighting the need for further research and development in this field. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 25, 2024 Category: Rheumatology Authors: Scott A. Rodeo Source Type: research
Immune tolerance of citrullinated peptides
Nature Reviews Rheumatology, Published online: 23 January 2024; doi:10.1038/s41584-024-01081-0Re-establishing tolerance to autoantigens is an important aim for the treatment of rheumatoid arthritis (RA). Immunization of HLA-DR4 transgenic mice with citrullinated self-antigens can induce immune tolerance, which suggests that such antigens could have a therapeutic role in anti-citrullinated peptide antibody-positive RA. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 23, 2024 Category: Rheumatology Authors: Ranjeny Thomas William H. Robinson Source Type: research
Engineering approaches for RNA-based and cell-based osteoarthritis therapies
Nature Reviews Rheumatology, Published online: 22 January 2024; doi:10.1038/s41584-023-01067-4This Review explores the potential of emerging RNA-based technologies and cell-engineering strategies, including those that incorporate small interfering RNA, microRNA, mRNA and synthetic receptor-mediated gene editing, to provide innovative and targeted approaches to osteoarthritis therapy. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 22, 2024 Category: Rheumatology Authors: Carlisle R. DeJulius Bonnie L. Walton Juan M. Colazo Richard d ’Arcy Nora Francini Jonathan M. Brunger Craig L. Duvall Source Type: research
Raynaud phenomenon: from GWAS to drug repurposing
Nature Reviews Rheumatology, Published online: 16 January 2024; doi:10.1038/s41584-024-01076-xThe identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 16, 2024 Category: Rheumatology Authors: Ariane L. Herrick Gisela Orozco Source Type: research
Proposals for the rheumatological use of JAK inhibitors
Nature Reviews Rheumatology, Published online: 12 January 2024; doi:10.1038/s41584-023-01068-3Janus kinase inhibitors have therapeutic potential for patients with immune-mediated inflammatory diseases, and evidence of greater risks of cardiovascular disease and malignancy than with TNF inhibitors should be carefully considered before recommendations against their use are made. Assessment of the risk–benefit ratios in these patients can instead guide clinical decision-making. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 12, 2024 Category: Rheumatology Authors: Francesco Ciccia Roberto Caporali Source Type: research
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Nature Reviews Rheumatology, Published online: 12 January 2024; doi:10.1038/s41584-023-01062-9Concerns have been raised about the safety of Janus kinase (JAK) inhibitors. This Review summarizes the evidence regarding the risks and benefits of JAK inhibitors to clarify which patients are most at risk of adverse events and guide clinical decision-making. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - January 12, 2024 Category: Rheumatology Authors: Zolt án Szekanecz Maya H. Buch Christina Charles-Schoeman James Galloway George A. Karpouzas Lars Erik Kristensen Steven R. Ytterberg Attila Hamar Roy Fleischmann Source Type: research
